The Brazilian Unified Health System (SUS) has approved the use of the antibiotic doxycycline as a new post-exposure prophylaxis (DoxiPEP) aimed at preventing infections of chlamydia and syphilis following unprotected sexual contact. The decision was made by the Ministry of Health and marks the first time that oral prevention against these sexually transmitted infections (STIs) has been adopted within the public health system. This initiative, which is backed by the National Commission for the Incorporation of Technologies (Conitec), involves the administration of two doxycycline pills after potential exposure to STIs.

The rollout of this treatment will initially focus on vulnerable populations, including gay cisgender men, bisexual individuals, other men who have sex with men, and transgender women who have experienced an STI incident in the past year. The Ministry of Health emphasizes that this strategy is specifically designed to mitigate the growing incidence of acquired syphilis, which has become a significant public health concern in Brazil. With these measures, the government aims to provide better health outcomes for communities most at risk.

Overall, the inclusion of doxycycline in the SUS not only reflects a proactive approach to addressing the increasing rates of STIs but also underscores a commitment to expand preventive measures within Brazil’s healthcare framework. This initiative may serve as a model for other countries dealing with similar public health challenges, especially as global rates of syphilis and chlamydia continue to rise.